Table 2.
Summary of patients with receptor tyrosine kinase amplification and distant metastasis
| Patient No. | Age | Gender | Smoking history | Alcohol history | Subsite | FFPE sample | Histological differentiation | T status | N status | Stage | Distant metastasis | Outcome | RTK amplification | Somatic mutation | Copy number alteration | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amplification | Deletion | |||||||||||||||
| 1 | 56 | M | Never | Yes | BM | B | M/D | 1 | 0 | I | ‐ | NED | EGFR | CDKN2A, KIT | – | – |
| 2 | 29 | F | UNK | UNK | TON | B | W/D | 1 | 0 | I | – | LTF | EGFR | – | GNA11, JAK3 | CDKN2A, RB1 |
| 3 | 67 | M | Former | Yes | GUM | B | W/D | 1 | 0 | I | – | NED | MET | ATM | PIK3CA | – |
| 4 | 41 | F | Never | Yes | TON | B | W/D | 1 | 0 | I | – | NED | FLT3 | – | PIK3CA | HNF1A, NOTCH1, STK11 |
| 5 | 76 | F | Never | Yes | GUM | B | W/D | 1 | 0 | I | – | NED | MET | TP53 | PIK3CA | HNF1A, NOTCH1, PTEN, STK11, TP53 |
| 6 | 36 | M | UNK | UNK | TON | B | W/D | 2 | 0 | II | – | NED | EGFR | – | – | – |
| 7 | 21 | F | Never | No | TON | B | M/D | 2 | 0 | II | – | NED | EGFR | – | – | – |
| 8 | 78 | M | Former | Yes | GUM | P | M/D | 2 | 0 | II | – | NED | EGFR | KIT | – | CDKN2A, RB1 |
| 9 | 53 | M | Current | Yes | TON | B | W/D | 2 | 0 | II | – | NED | EGFR, FGFR1 | SMARCB1 | – | CDKN2A, RB1 |
| 10 | 30 | M | Current | No | TON | B | W/D | 2 | 0 | II | – | NED | FGFR1 | TP53 | – | CDKN2A |
| 11 | 35 | F | Never | No | TON | B | P/D | 2 | 0 | II | – | NED | EGFR | – | AKT1, HRAS | PTEN, RB1 |
| 12 | 35 | F | Current | Yes | TON | B | M/D | 2 | 0 | II | – | NED | EGFR | CDKN2A | GNA11, JAK3 | – |
| 13 | 52 | M | Former | Yes | GUM | B | M/D | 2 | 0 | II | – | NED | ERBB4 | – | PIK3CA | – |
| 14 | 30 | M | Current | Yes | TON | B | M/D | 2 | 0 | II | – | NED | EGFR | JAK2, RET | – | – |
| 15 | 65 | M | UNK | UNK | BM | B | P/D | 2 | 0 | II | – | NED | FGFR3 | – | AKT1, ALK | ATM, CDKN2A, RB1 |
| 16 | 35 | F | Never | No | TON | B | W/D | 2 | 0 | II | – | NED | ERBB4 | – | PIK3CA | – |
| 17 | 65 | F | Current | Yes | TON | B | P/D | 2 | 0 | II | – | NED | ERBB2 | CDKN2A | – | – |
| 18 | 74 | F | Never | No | GUM | B | M/D | 2 | 1 | III | – | NED | FGFR1 | – | – | – |
| 19 | 36 | M | Current | Yes | TON | B | M/D | 2 | 1 | III | – | LTF | EGFR | CDKN2A | – | – |
| 20 | 62 | F | Current | No | GUM | B | M/D | 3 | 0 | IVA | – | NED | EGFR | KRAS | ABL1 | – |
| 21 | 75 | F | Never | UNK | GUM | B | M/D | 4a | 0 | IVA | – | DID | EGFR | – | – | CDKN2A |
| 22 | 54 | F | Never | No | TON | P | M/D | 2 | 2b | IVA | – | NED | FGFR3 | TP53 | ABL1, AKT1, CSF1R, GNA11, HRAS, JAK3, RET, SMO | RB1 |
| 23 | 63 | M | Current | Yes | TON | B | W/D | 3 | 2b | IVA | – | NED | ERBB2 | – | – | – |
| 24 | 50 | M | Current | Yes | FOM | B | M/D | 3 | 2b | IVA | – | NED | FGFR1 | – | ABL1, GNA11, GNAQ, JAK3 | CDKN2A |
| 25 | 73 | M | Current | Yes | FOM | B | M/D | 4a | 2c | IVA | – | NED | ERBB2 | PIK3CA | PIK3CA | CDKN2A |
| 26 | 82 | F | Former | No | GUM | B | W/D | 4a | 2c | IVA | – | NED | ERBB4 | – | – | – |
| 27 | 62 | M | UNK | UNK | HP | B | M/D | 4a | 2c | IVA | – | DOD(P,N) | ERBB2 | – | – | CDKN2A |
| 28 | 45 | M | Never | Yes | GUM | B | W/D | 4b | 1 | IVB | – | NED | EGFR | TP53 | AKT1 | – |
| 29 | 58 | M | UNK | UNK | FOM | B | M/D | 2 | 0 | II | Lung | DOD(M) | EGFR | TP53 | – | CDKN2A, PTEN |
| 30 | 62 | M | Current | Yes | BM | B | W/D | 4a | 0 | IVA | Lung | DOD(M) | FGFR1 | CDKN2A, GNA11, PIK3CA, TP53 | – | – |
| 31 | 57 | F | Former | Yes | GUM | P | W/D | 4a | 0 | IVA | Lung, bone | DOD(M) | ERBB2, FGFR3 | PIK3CA | ABL1, GNA11, GNAQ, HRAS, JAK2, JAK3, RET, SMO | APC, SMAD4 |
| 32 | 24 | M | Never | No | TON | B | M/D | 1 | 2b | VIA | Lung | DOD(M) | EGFR, ERBB2, FGFR3, KIT, MET, PDGFRA | ATM, ERBB4, FGFR3, IDH2, KDR, RB1, SMAD4, STK11, TP53 | ABL1, GNA11, GNAQ, JAK3, RET | CDKN2A, RB1, SMAD4 |
| 33 | 55 | M | Never | No | BM | LN | W/D | 2 | 2b | IVA | Lung | DOD(N,M) | FGFR3 | CDH1, TP53 | ABL1, AKT1, RET | ATM, PTEN, RB1 |
| 34 | 58 | F | Never | Yes | TON | B | W/D | 2 | 2c | IVA | Lung | DOD(P,N,M) | ERBB2, FLT3 | – | – | – |
| 35 | 63 | F | Former | Yes | TON | B | M/D | 3 | 2c | IVA | Lung | DOD(N,M) | EGFR | TP53 | – | – |
| 36 | 53 | M | Never | Yes | TON | B | M/D | 4a | 2c | IVA | Lung, bone | DOD(M) | EGFR, FGFR1, FGFR3 | – | AKT1, GNA11, JAK3 | RB1 |
| 37 | 62 | F | Current | Yes | TON | B | M/D | 4a | 2c | IVA | Lung, bone, liver | DOD(M) | FGFR1 | APC,TP53 | – | – |
| 38 | 71 | M | Current | Yes | BM | LN | P/D | 2 | 1 | III | Lung | DOD(M) | – | CDKN2A, TP53 | – | – |
| 39 | 74 | F | Former | UNK | BM | P | M/D | 2 | 1 | III | Lung | DOD(M) | – | – | CSF1R | – |
| 40 | 66 | M | Current | Yes | GUM | B | W/D | 4a | 1 | IVA | Lung, bone | AWD | – | TP53 | – | CDKN2A |
| 41 | 73 | M | Never | Yes | TON | P | P/D | 1 | 2b | IVA | Lung | DOD(M) | – | SMO | – | – |
| 42 | 69 | M | Current | Yes | TON | P | W/D | 2 | 2b | IVA | Lung | DOD(M) | – | – | AKT, CSF1R, HRAS | RB1 |
| 43 | 65 | M | UNK | Yes | TON | B | P/D | 2 | 2b | IVA | Lung | DOD(M) | – | TP53 | – | – |
| 44 | 62 | M | Never | Yes | BM | B | P/D | 2 | 2b | IVA | Lung | DOD(M) | – | TP53 | PIK3CA | TP53 |
| 45 | 74 | M | Current | No | BM | B | P/D | 2 | 2b | IVA | Lung | DOD(M) | – | – | – | TP53 |
| 46 | 32 | M | Never | Yes | TON | B | M/D | 2 | 2b | IVA | Lung, bone | DOD(M) | – | SMARKB1 | – | – |
| 47 | 65 | M | Current | Yes | TON | B | M/D | 3 | 2b | IVA | Lung, bone, liver | DOD(M) | – | TP53 | – | – |
| 48 | 67 | M | Current | Yes | TON | B | W/D | 2 | 2c | IVA | Lung | DOD(M) | – | TP53 | PIK3CA | STK11, TP53 |
| 49 | 71 | F | Never | No | GUM | B | M/D | 4a | 2c | IVA | Lung | DOD(N,M) | – | – | – | – |
The upper part of the table shows patients with RTK amplification (Patients 1–28), the middle shows patients with both RTK amplification and distant metastasis (29–37), and the lower part shows patients with distant metastasis (38–49). AWD, alive with disease; B, biopsy sample; BM, buccal mucossa; DID, died of intercurrent disease; DOD, died of disease; F, female; FOM, floor of mouth; HP, hard palate; LN, lymph node sample; LTF, lost to follow up; M, male; M/D, moderately differentiated; NED, no evidence of disease; P, primary sample of surgical specimen; P/D, poorly differentiated; TON, tongue; UNK, unknown; W/D, well differentiated.